AstraZeneca

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.

Results: 1-12 of 13

ASTRAZENECA’S IMFINZI (DURVALUMAB) RECOMMENDED BY NICE FOLLOWING MHRA APPROVAL AS FIRST IMMUNOTHERAPY IN COMBINATION WITH PERIOPERATIVE CHEMOTHERAPY IN RESECTABLE GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER

FIRST NICE RECOMMENDED TARGETED TREATMENT OPTION FOR ELIGIBLE PATIENTS LIVING WITH UNRESECTABLE LOCALLY ADVANCED STAGE III EGFR-MUTATED LUNG CANCER

AstraZeneca and Northern Ireland Forge New Strategic Partnership Aiming to Transform Healthcare and Boost Innovation

PATIENTS IN SCOTLAND GAIN ACCESS TO CANCER TREATMENTS FOR LUNG CANCER AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING SMC DECISIONS

The UN at 80: Every Human Deserves a Longer, Healthier Future

DELAYS IN CANCER TESTING ARE IMPACTING PATIENTS’ ACCESS TO TARGETED THERAPIES, NEW STUDY SUGGESTS

Innovation

MORE PATIENTS ACROSS ENGLAND AND WALES ARE SET TO BECOME ELIGIBLE FOR ASTRAZENECA’S FORXIGA (DAPAGLIFLOZIN) FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

LYNPARZA (OLAPARIB) ACCEPTED FOR USE IN SCOTLAND TO TREAT GERMLINE BRCA-MUTATED HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER CHEMOTHERAPY

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

IMFINZI (DURVALUMAB) IN COMBINATION WITH CHEMOTHERAPY RECEIVES POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER